Swedish Orphan Biovitrum AB (Sobi) today announced that Birgitte Volck, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer (CMO) of Sobi, will leave the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases.
Birgitte will work through a six month notice period before leaving Sobi.
“We thank Birgitte for her leadership and dedication which has helped to evolve Sobi’s patient oriented research and development organisation into a highly skilled international team”, said Geoffrey McDonough, President and CEO of Sobi. “Birgitte joined Sobi in 2012 and has been instrumental in advancing Sobi’s late stage development projects and in bringing new treatment options to people with rare diseases.”
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).